secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001628280-26-019045
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1
--------------------------------------------------------------------------------

- $60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.
- OV329 7 mg cohort: no treatment-related adverse events; Phase 2 for focal onset seizures planned for Q2 2026.
- OV329 development expanded to tuberous sclerosis complex seizures (Q4 2026) and infantile spasms (2027).
- OV4071 (oral KCC2 activator) received HREC/TGA approval; Phase 1 in Australia starts Q2 2026.
- Cash $90.4M at Dec 31, 2025; net loss FY2025 $17.4M ($0.23/share); Series A warrants could add $53.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/0001628280-26-019045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovid-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-019045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer